Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ESR1 | P03372 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | HRH2 | P25021 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.97 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL4622977 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262757 | 0.99 | CHRM3 (0.95) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29635996 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082133-A | Synthetic method of tulobuterol | 上海医药工业研究院 | 2023-05-09 | — | — | CN | claimed |
| CN-111925294-A | Tolterodine pamoate and preparation method thereof | 济南大学 | 2020-11-13 | — | — | CN | claimed |
| CN-103044273-B | Synthesis method of tolterodine tartrate | LIVZON SYNTPHARM CO LTD ZHUHAI FTZ | 2014-12-24 | — | — | CN | claimed |
| CN-103044273-A | Synthesis method of tolterodine tartrate | LIVZON SYNTPHARM CO LTD ZHUHAI FTZ | 2013-04-17 | — | — | CN | claimed |
| US-20120041235-A1 | PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-02-16 | — | — | US | claimed |
| EP-2398765-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | Pharmathen S.A. (GR) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094292-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2010-08-26 | — | — | WO | claimed |
| EP-1194134-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE UTILIZATION OF TOLTERODINE | HEXAL AG (DE) | 2002-04-10 | — | — | EP | claimed |
| WO-2001003678-A2 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE UTILIZATION OF TOLTERODINE | HEXAL AG (DE) | 2001-01-18 | — | — | WO | claimed |
| CN-118393009-A | Analysis method of tolote Luo Zhong related substances | 正大制药（青岛）有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118159223-A | Ocular devices and methods | 文奇制药公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117129595-B | Analysis method of tolote Luo Zhong related substances | 正大制药（青岛）有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117129595-A | Analysis method of tolote Luo Zhong related substances | 正大制药（青岛）有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117054559-A | Analysis method of genotoxic impurities in tulobuterol | 正大制药（青岛）有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-1194134-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE UTILIZATION OF TOLTERODINE | HEXAL AG (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001003678-A2 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE UTILIZATION OF TOLTERODINE | HEXAL AG (DE) | 2001-01-18 | — | — | WO | disclosed |
| CN-1238768-A | Process for preparing tolterodine | UPJOHN CO (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0960109-A1 | PROCESS TO PREPARE TOLTERODINE | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5922914-A | REDUCING 2,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH A REDUCING AGENT TO FORM 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-OL CHEMICAL INTERMEDIATE, REDUCTIVELY AMINATING THE HYDROXY COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1998029402-A1 | PROCESS TO PREPARE TOLTERODINE | PHARMACIA & UPJOHN COMPANY (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041235-A1 | PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PAH, UGT1A7, MLN | CHRM3 228/4885CHRM2 617/4885CHRM1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.